Following its latest funding round, Rosa Biotech has announced plans to accelerate development of its bio-sensing technology, designed to enable cost effective screening of a range of diseases with high accuracy at an early stage.
Acesion Pharma has announced positive data from pre-clinical studies with AP31969, developed for chronic oral maintenance treatment to prevent atrial fibrillation (AF) recurrence.
Pfizer is building a $200m (€179m) R&D centre in Chesterfield, Missouri at which it will consolidate biotherapeutics process development operations in the region.
Morphotek Inc has launched an antibody-drug conjugate (ADC) services business incorporating its RESPECT site-specific conjugation technology and eribulin-linker toxin platform.
Correctly identifying cell lines used in cancer drug development would cut the amount US researchers spend on preclinical research that cannot be reproduced.
Boehringer Ingelheim has entered a collaboration to develop a peptide candidate for cardio-metabolic diseases in a deal that could net partner Zealand Pharma up to €295m ($395m).
Ambrx and Zhejiang Medicine have selected Wuxi to accelerate the development of a potential ADC (antibody drug conjugate) targeting Her2-positive breast cancer.
Goodwin Biotechnology has teamed up with Coldstream Laboratories to offer clients ADC services as another example of biopharma demand driving contract manufacturing and development.
Construction of the UK National Biomanufacturing Centre, an
ambitious project aimed at helping biotechnology start-ups get
their product ideas into clinical trials, is progressing on
schedule and should be ready to start production...
